Heinemann Lutz
Science Consulting in Diabetes GmbH, Düsseldorf, Germany.
J Diabetes Sci Technol. 2025 Mar;19(2):475-480. doi: 10.1177/19322968231204625. Epub 2023 Oct 9.
Optimizing glucose control is of interest also for patients with type 2 diabetes (T2D). While systems for automated insulin delivery are widely used for patients with type 1 diabetes, as documented by many publications, this is not the case with T2D. Because of the number of such patients, this will change drastically in the next years. Manufacturers can transfer many learnings from type 1 to type 2; however, specific clinical aspects have to be considered. This commentary will discuss these aspects and some of the current activities. Future automated insulin delivery (AID) systems will take data from multisensor systems into account to individualize the AID algorithm, supported by artificial intelligence. There is a high need to document the benefits of AID systems in this patient group.
优化血糖控制对于2型糖尿病（T2D）患者也很重要。正如许多出版物所记载的，虽然自动胰岛素输送系统广泛应用于1型糖尿病患者，但T2D患者并非如此。鉴于此类患者的数量，在未来几年这种情况将发生巨大变化。制造商可以将许多从1型糖尿病中学到的经验应用于2型糖尿病；然而，必须考虑特定的临床方面。本评论将讨论这些方面以及一些当前的活动。未来的自动胰岛素输送（AID）系统将考虑来自多传感器系统的数据，以在人工智能的支持下使AID算法个性化。非常有必要记录AID系统在该患者群体中的益处。
